AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|
25.1 C
New York
Thursday, September 3, 2026

Tag: trial

newssourceFORcompanyinformationcontent1releasesmarket

Natural DHT Blockers Take Center Stage in Hair Loss Defense — HairSmart Leads the Charge with Award-Winning Formula

HairSmart’s award-winning natural DHT Blocker offers a safe, plant-based solution to combat hair loss, clinically proven, side-effect-free, and effective.

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

Young Mother’s Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC

VANCOUVER, BC, Aug. 14, 2025 /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in...

Polar Power Reports Second Quarter 2025 Financial Results

GARDENA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup, and solar hybrid DC power solutions, reports its financial results for the three months ended June 30, 2025.

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Dried Plasma Innovation Addresses Critical Global Need

Velico's FrontlineODP™ Spray Dried Plasma Achieves Key Milestone with First-in-Human Safety Trial BEVERLY, Mass., Aug. 14, 2025 /PRNewswire/ -- Trauma doesn't wait, and neither should...

Renowned Winston & Strawn Trial Lawyer, Appellate Judge Pen Updated Version of Well-Received Trial Guide

American Bar Association publishes 2nd edition of 'On the Jury Trial' DALLAS, Aug. 14, 2025 /PRNewswire/ -- Eight years after they published a bestselling how-to guide...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers